Celgene in two Thalomid deals

CELG granted Pharmion ( Cambridge, U.K.) exclusive licenses to its intellectual property covering Thalomid thalidomide and preclinical and clinical data necessary to support international regulatory filings for the product. CELG will receive a royalty from Pharmion, and retains rights to Thalomid in North America, China, Japan and Taiwan. CELG also obtained an option to acquire an equity stake in Pharmion. ...